Suppression of Staphylococcus aureus virulence by a small-molecule compound

Proceedings of the National Academy of Sciences of the United States of America
Peng GaoRichard Yi Tsun Kao

Abstract

Emerging antibiotic resistance among bacterial pathogens has necessitated the development of alternative approaches to combat drug-resistance-associated infection. The abolition of Staphylococcus aureus virulence by targeting multiple-virulence gene products represents a promising strategy for exploration. A multiplex promoter reporter platform using gfp-luxABCDE dual-reporter plasmids with selected promoters from S. aureus-virulence-associated genes was used to identify compounds that modulate the expression of virulence factors. One small-molecule compound, M21, was identified from a chemical library to reverse virulent S. aureus into its nonvirulent state. M21 is a noncompetitive inhibitor of ClpP and alters α-toxin expression in a ClpP-dependent manner. A mouse model of infection indicated that M21 could attenuate S. aureus virulence. This nonantibiotic compound has been shown to suppress the expression of multiple unrelated virulence factors in S. aureus, suggesting that targeting a master regulator of virulence is an effective way to control virulence. Our results illustrate the power of chemical genetics in the modulation of virulence gene expression in pathogenic bacteria.

References

Aug 17, 2002·Infection and Immunity·Sharon J PeacockNicholas P J Day
Jun 7, 2003·Molecular Microbiology·Dorte FreesHanne Ingmer
Jun 4, 2004·Journal of Bacteriology·Jinxin Gao, George C Stewart
Jun 22, 2005·Journal of Bacteriology·Indranil ChatterjeeMathias Herrmann
Nov 1, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yukiko K Stranger-JonesOlaf Schneewind
Nov 17, 2007·Cell Host & Microbe·Victor J TorresEric P Skaar
Dec 15, 2007·Nature Reviews. Microbiology·Lynette CegelskiScott J Hultgren
Jul 22, 2008·Current Opinion in Chemical Biology·Sonia Escaich
Oct 14, 2008·Journal of the American Chemical Society·Thomas Böttcher, Stephan A Sieber
Jan 13, 2009·Investigative Ophthalmology & Visual Science·Clare C McCormickRichard J O'Callaghan
Jun 16, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Alice G ChengDominique M Missiakas
Jan 19, 2010·Nature Reviews. Drug Discovery·David A Rasko, Vanessa Sperandio
Jun 1, 2010·Nature Biotechnology·Richard Y KaoKwok-Yung Yuen
May 6, 2011·Angewandte Chemie·Sebastian R GeigerPatrick Cramer
Aug 27, 2011·Chemistry & Biology·Fei SunChuan He
May 5, 2012·Chemical Biology & Drug Design·Reaz UddinZaheer Ul-Haq
Aug 25, 2012·Frontiers in Cellular and Infection Microbiology·Michele J AndersonMarnie L Peterson
Dec 14, 2012·Nature·Francis AlonzoVictor J Torres
Jan 9, 2013·Journal of Medicinal Chemistry·Christopher P GordonWeng C Chan
Jan 25, 2014·International Journal of Medical Microbiology : IJMM·Dorte FreesHanne Ingmer

❮ Previous
Next ❯

Citations

May 10, 2020·The Journal of Infectious Diseases·Gyu-Lee KimDane Parker
Dec 30, 2020·Chemical Reviews·Jed F Fisher, Shahriar Mobashery
Nov 20, 2020·Journal of Proteome Research·Volker C KirschStephan A Sieber
Oct 28, 2019·Environmental Science & Technology·Ferdi L HellwegerVanni Bucci
Sep 3, 2021·Biochemical Pharmacology·Shisong JingDacheng Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.